ASH1L and attention deficit-hyperactivity disorder: Additional pathogenic variants in ASH1L have been associated with Attention-deficit/hyperactivity disorder (ADHD) (Satterstrom et al., 2019), Tourette syndrome (Liu et al., 2020; Zhang et al., 2021), and epilepsy (Tang et al., 2020).